GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » EV-to-FCF

BeiGene (SHSE:688235) EV-to-FCF : -18.07 (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BeiGene's Enterprise Value is ¥135,390 Mil. BeiGene's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-7,491 Mil. Therefore, BeiGene's EV-to-FCF for today is -18.07.

The historical rank and industry rank for BeiGene's EV-to-FCF or its related term are showing as below:

SHSE:688235' s EV-to-FCF Range Over the Past 10 Years
Min: -151.73   Med: -9.89   Max: -3.9
Current: -17.98

During the past 11 years, the highest EV-to-FCF of BeiGene was -3.90. The lowest was -151.73. And the median was -9.89.

SHSE:688235's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs SHSE:688235: -17.98

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), BeiGene's stock price is ¥162.01. BeiGene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-4.586. Therefore, BeiGene's PE Ratio (TTM) for today is At Loss.


BeiGene EV-to-FCF Historical Data

The historical data trend for BeiGene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene EV-to-FCF Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.48 -12.96 -13.57 -9.67 -9.44

BeiGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.70 -9.44 -9.33 -10.02 -21.36

Competitive Comparison of BeiGene's EV-to-FCF

For the Biotechnology subindustry, BeiGene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BeiGene's EV-to-FCF falls into.



BeiGene EV-to-FCF Calculation

BeiGene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=135389.563/-7490.723
=-18.07

BeiGene's current Enterprise Value is ¥135,390 Mil.
BeiGene's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-7,491 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene  (SHSE:688235) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BeiGene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=162.01/-4.586
=At Loss

BeiGene's share price for today is ¥162.01.
BeiGene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-4.586.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BeiGene EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BeiGene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

BeiGene Headlines

No Headlines